Form 4: Bristol-Myers Squibb Director Boosts Equity Holdings

Bristol-Myers Squibb Director Peter J. Arduini acquired 748.337 Deferred Share Units, increasing his total beneficial ownership to 64,620.164 units.

Summary

• Peter J. Arduini, a Director of Bristol-Myers Squibb Company (BMY), acquired 748.337 Deferred Share Units (DSUs).
• The transaction date for the acquisition was September 30, 2025.
• Each Deferred Share Unit will be converted into one share of common stock upon settlement.
• Settlement of the DSUs occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.
• Following this acquisition, Arduini beneficially owns a total of 64,620.164 Deferred Share Units.
• The reported DSUs include deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Sentiment

Score: 6

Explanation: Slightly positive as it indicates a director's continued equity interest and alignment with shareholders, though it's a compensation grant rather than an open market purchase.

Positives

• Director Peter J. Arduini increased his beneficial ownership in Bristol-Myers Squibb by acquiring 748.337 Deferred Share Units.
• The acquisition of DSUs, which convert to common stock, aligns the director's interests with long-term shareholder value.

Negatives

• The acquisition is of Deferred Share Units, not direct common stock, meaning the shares are not immediately available for sale.
• The transaction price for the DSUs was $0, indicating they were likely granted as part of compensation rather than purchased.

Risks

• The value of the Deferred Share Units is tied to the future performance of Bristol-Myers Squibb's common stock.
• Settlement of the DSUs is deferred until the reporting person ceases to be a director or a future specified date, introducing a time-based risk to liquidity.

Future Outlook

The Deferred Share Units will convert into shares of common stock upon settlement, which will occur when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

This is a routine insider transaction filing and does not provide specific insights into broader pharmaceutical industry trends or competitive landscape.

Related Party Transactions

• The acquisition of Deferred Share Units represents compensation provided to a non-employee director under the company's 1987 Deferred Compensation Plan.

Stakeholder Impact

• Shareholders may view the director's increased equity stake as a positive sign of alignment with long-term company performance.
• The transaction is part of the compensation structure for non-employee directors, impacting the company's overall compensation expenses.

Next Steps

• The Deferred Share Units will be converted into common stock upon the reporting person ceasing to be a director or at a future specified date.

Key Dates

Recommendation

This Form 4 filing details a routine compensation-related acquisition of Deferred Share Units by a director. While it shows continued insider alignment, it does not represent a significant change in the company's fundamental outlook or financial performance that would warrant a change in investment recommendation based solely on this filing.

Keywords

Bristol-Myers Squibb, BMY, Insider Trading, Form 4, Deferred Share Units, Director Compensation, Equity Holdings, Peter J. Arduini